Genentech CEO snags $14M in pay as shares swoon

Genentech CEO Arthur Levinson (photo) scooped up close to $14 million in compensation last year, even as its stock price slid in the face of slowing cancer therapy revenues. Levinson declined a raise, keeping his income under the million-dollar mark, and there was $2.7 million in bonuses for meeting his goals for the year. According to a review by the AP, Levinson also took home about $10 million in stock options and perks that included $97,375 for home security.

- read the AP analysis

ALSO: Johnson & Johnson honcho Bill Weldon (photo) nabbed a 22 percent hike in compensation in 2007. Between base salary of $1.73 million, incentive pay of $9.19 million, plus stock awards and options and various miscellaneous perks, he raked in $25.1 million in compensation. Report

Related Articles:
Genentech successes pay off big for CEO. Report
Genentech touts pipeline prospects as doubts fester. Report
Genentech fights to keep edge in drug development. Report
Genentech hiring researchers in big R&D push. Report

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.